Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.39 |
| ▸ | PDE2A | O00408 | 5/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | HAT1 | O14929 | 3/20 | 0.34 |
| ▸ | EP300 | Q09472 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23889076 | 0.89 | ROCK2 (0.41) | ROCK2PDE2APDE3APDE10ARET | |
| SCHEMBL17452665 | 0.88 | ROCK2 (0.49) | ROCK2PDE2APDE3APDE10APLA2G4A | |
| SCHEMBL17452670 | 0.87 | ROCK2 (0.40) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL21947339 | 0.87 | ROCK2 (0.44) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL17321452 | 0.86 | PDE2A (0.39) | ROCK2PDE2AHAT1EP300RET | |
| SCHEMBL19128286 | 0.86 | ROCK2 (0.39) | ROCK2PDE2APDE3APDE10ARET | |
| SCHEMBL20647024 | 0.85 | ROCK2 (0.40) | ROCK2PDE2APDE3APDE10ARET | |
| SCHEMBL23889125 | 0.85 | ROCK2 (0.36) | ROCK2PDE2ARETPLA2G4A | |
| SCHEMBL21946575 | 0.83 | PDE2A (0.37) | ROCK2PDE2ARET | |
| SCHEMBL21948591 | 0.83 | ROCK2 (0.40) | ROCK2PDE2APDE3APDE10APLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PDE2A 60/4885PDE3A 22/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PDE2A 60/4885PDE3A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.